EnClear Therapies is focused on enhancing the lives of patients with central nervous system (CNS) disorders through its innovative EnTrega CSF Platform. This proprietary technology enables precision dosing of therapeutics directly to targeted areas within the CNS, addressing significant challenges associated with traditional delivery methods. The platform utilizes a closed-loop cerebrospinal fluid (CSF) control system integrated with machine learning and artificial intelligence, allowing for controlled, continuous, and personalized delivery of medications. This approach not only optimizes dosage profiles to achieve effective therapeutic levels but also minimizes the risk of severe side effects and peripheral toxicity, which are common issues with conventional treatments.

The EnTrega CSF Platform is particularly advantageous in overcoming barriers such as the Blood-Brain Barrier and other protective membranes that hinder effective drug delivery. By facilitating localized CNS delivery, the platform ensures that therapeutics reach critical areas of the brain in higher concentrations than standard care methods. Additionally, EnClear Therapies aims to improve patient access and logistics by transitioning CNS therapies from specialized hospitals to local infusion clinics, thereby enhancing the overall quality of life for patients through more convenient treatment options.

United States

At EnClear Therapies, we are combining Bioscience & Med-tech expertise to develop solutions that improve and extend the lives of patients with CNS disease.

The team at EnClear is developing systems and medical interventions that Access, Recirculate & Modify CSF for:
›	Targeted removal of toxicity from CSF correlated to neurodegenerative disease progression.
›	Continuous localized delivery of therapeutics & monitoring of CSF to ensure effective and personalized therapy.

EnClear Therapies

Company Details